Inventor · disambiguated record
John Najim
Also filed as: NAJIM JOHN
23 granted patents·27 pending applications·487 citations·filing 2021–2025
97Inventor score
Top patents by PatentIndex Score
50 records- 0199US12329824B1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Granted Jun 17, 2025·4 cites·30 claims
- 0299US12239717B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 0399US12239716B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 0499US12144867B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 0599US12144868B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 0699US12102687B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Oct 1, 2024·17 cites·30 claims
- 0799US11986537B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted May 21, 2024·24 cites·19 claims
- 0899US11969475B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Apr 30, 2024·25 cites·30 claims
- 0999US11844843B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 19, 2023·30 cites·30 claims
- 1099US11839660B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·30 cites·16 claims
- 1199US11771776B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·32 cites·19 claims
- 1299US11759525B1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Sep 19, 2023·32 cites·22 claims
- 1399US11679161B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 20, 2023·38 cites·25 claims
- 1499US11672872B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·37 cites·21 claims
- 1599US11648318B2Anti-transferrin receptor (TFR) antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted May 16, 2023·37 cites·9 claims
- 1699US11638761B2Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted May 2, 2023·47 cites·24 claims
- 1799US11633498B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Apr 25, 2023·37 cites·30 claims
- 1897US11931421B2Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Mar 19, 2024·26 cites·7 claims
- 1995US12128109B2Muscle targeting complexes and formulations for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·17 cites·28 claims
- 2092US2025360223A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2190US12440574B2Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·22 claims
- 2290US12403203B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Sep 2, 2025·0 cites·19 claims
- 2388US2025367310A1Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2486US12440575B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Granted Oct 14, 2025·0 cites·30 claims
- 2584US2025339553A1Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2680US12397062B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Granted Aug 26, 2025·0 cites·30 claims
- 2771US2025057972A1Muscle targeting complexes and formulations for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2865US2024382513A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2965US2023203180A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3065US2025249117A1Dosing of muscle targeting complexes for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3164US2024318177A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3264US2024382609A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3364US2025099603A9Muscle targeting complexes and uses thereof for treating friedreich's ataxiaDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3464US2024318176A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3564US2025249116A1Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3664US2024209119A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3764US2025025570A1Muscle targeting complexes for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3864US2024368296A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3964US2024294921A1Muscle targeting complexes and uses thereof for treating pompe diseaseDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4061US2023285586A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4161US2024117356A1Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4260US2025018050A1Dosing of muscle targeting complexes for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4359US2024325558A1Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4459US2024110184A1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4558US2024016952A1Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4658US2023287108A1Muscle-targeting complexes and uses thereofDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4758US2023346966A1Muscle-targeting complexes and uses thereof in treating muscle atrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4856US2023256112A1Anti-transferrin receptor (tfr) antibody and uses thereofDYNE THERAPEUTICS LNC·Filed 2021·Application pending·0 cites
- 4956US2023272065A1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5056US2024100177A1Antibody-oligonucleotide complexes and uses thereofDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Najim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →